7 completed, 1 active not recruiting, 1 recruiting, 1 withdrawn. 10 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 7, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Refractory Primary Central Nervous System Neoplasm: new trials by email Literature Review of Refractory Primary Central Nervous System Neoplasm trials Research Report on Refractory Primary Central Nervous System Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors LUTATHERA® (Lutetium Lu 177 dotatate) - High Grade Glioma, Meningioma | Phase 1 / Phase 2 | Recruiting | Nationwide Children's Hospital | 65 | 2022-11-21 | 2026-07-20 |
| Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study Biospecimen Collection, Ipilimumab, Nivolumab - Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2021-05-11 | 2026-06-10 | |
| Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors Biospecimen Collection, Magnetic Resonance Imaging, Savolitinib - Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 41 | 2018-11-27 | 2026-07-30 |
| Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma Irinotecan, Pevonedistat, Temozolomide - Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm | Phase 1 | Completed | Children's Oncology Group | 30 | 2018-01-11 | 2024-10-22 |
| Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm | Phase 1 | Completed | Children's Oncology Group | 33 | 2017-08-15 | 2025-01-14 |
| Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Laboratory Biomarker Analysis, Pharmacokinetic (PK) study, Prexasertib - Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm | Phase 1 | Completed | Children's Oncology Group | 30 | 2017-02-27 | 2023-12-20 |
| Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Entinostat, Laboratory Biomarker Analysis, Pharmacological Study - Brain Stem Neoplasm, Pineal Region Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 21 | 2017-01-06 | 2023-10-17 |
| Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas Pharmacological Study, Selinexor - Malignant Glioma, Recurrent Brain Neoplasm | Phase 1 | Completed | Children's Oncology Group | 59 | 2015-10-30 | 2025-01-14 |
| Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Laboratory Biomarker Analysis, Pharmacological Study, Pomalidomide - Neurofibromatosis Type 1, Recurrent Childhood Brain Stem Glioma | Phase 1 | Completed | National Cancer Institute (NCI) | 29 | 2015-07-14 | 2022-04-25 |
| Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Melanoma | Phase 1 | Completed | National Cancer Institute (NCI) | 41 | 2012-11-14 | 2023-12-22 |
Central Nervous System Neoplasms (10) · Lymphoma (4) · Glioma (3) · Diffuse Intrinsic Pontine Glioma (2) · Medulloblastoma (2) · Astrocytoma (1) · Brain Neoplasms (1) · Brain Stem Neoplasms (1) · Carcinoma, Medullary (1) · Colorectal Neoplasms, Hereditary Nonpolyposis (1) · Ependymoma (1) · Hematologic Neoplasms (1) · Melanoma (1) · Meningioma (1) · Neoplasms, Germ Cell and Embryonal (1)
Neoplasms (10) · Neoplasms by Site (10) · Nervous System Diseases (10) · Nervous System Neoplasms (10) · Neoplasms by Histologic Type (8) · Neoplasms, Glandular and Epithelial (7) · Neoplasms, Nerve Tissue (7) · Neuroectodermal Tumors (7) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Neuroepithelial (6) · Brain Diseases (4) · Central Nervous System Diseases (4) · Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4)
Irinotecan (2) · Specimen Handling (2) · Temozolomide (2) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (1) · CTLA-4 Antigen (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Phantoms, Imaging (1) · X-Rays (1) · cabozantinib (1) · entinostat (1) · lutetium Lu 177 dotatate (1) · pevonedistat (1) · pomalidomide (1)
National Cancer Institute (NCI) (5) · Children's Oncology Group (4) · Nationwide Children's Hospital (1)
United States (10) · Canada (3)
Andrew Bukowinski (1) · Cynthia J Wetmore (1) · Daniel A Morgenstern (1) · Jason R Fangusaro (1) · Jennifer H Foster (1) · Julia Glade-Bender (1) · Margot Lazow, MD (1) · Meredith K Chuk (1) · Ralph Salloum (1) · Stuart L Cramer (1)
PMID 33881209, PMID 39487711, PMID 39998852
UM1CA097452 (6), UM1CA081457 (2), P30CA015704 (1), UM1CA154967 (1)